Targeted Oncology3d
FDA Fast Tracks Amezalpat for HCC Treatment
Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds ...
Monthly Prescribing Reference4d
Amezalpat Gets Fast Track Status for Hepatocellular Carcinoma
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
Cancer Therapy Advisor3d
Amezalpat Gets Fast Track Designation for HCC
The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.
Tempest Therapeutics granted FTD from FDA for amezalpat
Tempest Therapeutics (TPST) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to amezalpat, ...
Nasdaq4d
Tempest Therapeutics' Amezalpat Receives FDA Fast Track and Orphan Drug Designations for Hepatocellular Carcinoma Treatment
Tempest Therapeutics, Inc. announced that the FDA has granted Fast Track Designation to amezalpat (TPST-1120), an oral small molecule designed to treat hepatocellular carcinoma (HCC), recognizing ...
Morningstar4d
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
“This designation, following the Orphan Drug designation granted last month, reinforces the promise of amezalpat as a potential treatment option for patients affected by HCC. We look forward to ...
oncnursingnews2d
Amezalpat Receives FDA Fast Track Designation for Hepatocellular Carcinoma
Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.